Enfusion, Inc. (NYSE:ENFN - Get Free Report) saw an uptick in trading volume on Friday . 1,006,729 shares were traded during mid-day trading, an increase of 168% from the previous session's volume of 375,878 shares.The stock last traded at $9.45 and had previously closed at $9.30.
Enfusion Stock Performance
The firm has a market capitalization of $1.20 billion, a P/E ratio of 232.50, a PEG ratio of 2.42 and a beta of 0.93. The company has a 50-day simple moving average of $8.82 and a two-hundred day simple moving average of $8.85.
Enfusion (NYSE:ENFN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). Enfusion had a net margin of 1.70% and a return on equity of 6.93%. The firm had revenue of $49.46 million for the quarter, compared to analysts' expectations of $50.27 million. As a group, research analysts forecast that Enfusion, Inc. will post 0.07 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Enfusion
Several large investors have recently modified their holdings of ENFN. Allspring Global Investments Holdings LLC purchased a new stake in shares of Enfusion during the 1st quarter valued at $44,000. RiverPark Advisors LLC purchased a new position in Enfusion during the second quarter valued at $68,000. Arizona State Retirement System acquired a new stake in Enfusion in the 2nd quarter worth about $86,000. Price T Rowe Associates Inc. MD purchased a new stake in Enfusion during the 1st quarter valued at about $102,000. Finally, Quadrature Capital Ltd purchased a new position in shares of Enfusion during the 1st quarter worth $109,000. Institutional investors own 81.05% of the company's stock.
Enfusion Company Profile
(
Get Free Report)
Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Enfusion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enfusion wasn't on the list.
While Enfusion currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
